VBI Vaccines Inc. (VBIV) Hit 1-Year Low at $2.63

June 29, 2018 - By Estela Ashley

VBI Vaccines Inc. (NASDAQ:VBIV) Corporate Logo

VBI Vaccines Inc. (NASDAQ:VBIV) broke into one-year low with $2.42 price target or 8.00 % below the last $2.63 price per share. The one-year low was reported on Jun, 29 by Barchart.com. It has $168.89M market cap. At $2.42 price target, the company’s valuation could be $13.51M less.

VBIV is touching $2.63 during the last trading session, after decreased 4.71%.Currently VBI Vaccines Inc. is downtrending after 26.86% change in last June 29, 2017. VBIV has also 68,106 shares volume. VBIV underperformed by 39.43% the S&P 500.

There’s a significant VBI Vaccines Inc. (NASDAQ:VBIV) news published by Nasdaq.com. It’s an article titled: “VBI Vaccines to Present at 2018 JMP Securities Life Sciences Conference” on June 19, 2018.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally.The firm is valued at $168.89 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process.Currently it has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: